

# AETNA COVID CHANGES

On January 30, 2023, the federal government announced that the two national emergencies addressing COVID-19, the public health emergency (PHE) and the national emergency, will end on May 11, 2023. Starting May 12, 2023, health plans and group plan sponsors will no longer be subject to federal requirements for coverage of COVID-19 testing, vaccinations and treatments. Below is a summary of the changes to COVID-19 coverage that will take place once the federal emergencies end for fully insured plan sponsors.

	During the emergency period	Starting May 12, 2023
<b>COVID-19 vaccines, including boosters</b>	Members pay \$0 for the vaccine at any location.	Members pay \$0 for the vaccine at in-network locations.*
<b>COVID-19 at-home test kits, also known as over-the-counter, or OTC test kits</b>	Members pay \$0 for select test kits.  Plans cover eight OTC COVID- 19 tests per month with a \$0 member cost share, if obtained at a pharmacy, or with a post- service reimbursement claim.	Members will pay the retail cost of test kits. They are no longer covered.  Members will be able to get an at-home test kit for around \$12 per test, or \$24 for a box of two from CVS* and other retailers.  Members can also use funds from a health savings account or a flexible spending account toward test kits.
<b>COVID-19 lab tests and associated provider visits</b>	Members pay \$0 for lab tests, including rapid diagnostic and swab-and-send tests, at in-network locations.  Plans cover certain associated provider visits at \$0 cost share.	Members will pay their copay, co-insurance or deductible at in-network locations. It will be applied to their out-patient testing benefit, which is part of their medical plan.  Associated provider visits will also follow normal plan copay or coinsurance requirements.
<b>COVID-19 anti- viral medications or treatments, like Paxlovid*</b>	Members pay \$0 for these prescriptions.	No change. Members pay \$0 for these prescriptions while the government supply is available.
<b>Pharmacist Assessment and Prescribing of Paxlovid program</b>	Members pay \$0 for pharmacist assessment and prescribing of Paxlovid at pharmacies, including CVS.	No change.
<b>COVID-19 monoclonal antibody treatments</b>	Members pay normal cost sharing for EUA-approved monoclonal antibody treatments.*	No change. Members will continue to pay normal cost sharing for EUA-approved monoclonal antibody treatments.*
<b>COBRA, HIPAA, special enrollment, and benefit claims and appeals</b>	The national emergency extended deadlines for: <ul style="list-style-type: none"> <li>• COBRA elections</li> <li>• Paying COBRA premiums</li> <li>• Electing HIPAA special enrollment</li> <li>• Filing claims, appeals and requests for external review</li> </ul>	Deadlines return to normal timeframes starting July 10, 2023.

*\*Under an EUA declaration, the FDA may authorize unapproved medical products or unapproved uses of approved medical products to be used in an emergency to diagnose, treat, or prevent serious or life-threatening diseases or conditions.*

*Certain state COVID-19 coverage requirements may have expiration dates that are not tied to the end of the federal emergencies. Aetna will follow all federal and state mandates, as required.*

*We will continue to provide updates if needed. If you have any questions about these notices, or general inquiries, please contact your HR Business Partner.*